Soleno Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Soleno Therapeutics, Inc. (SLNO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-175.85-38.99-24.07-30.91-24.64-30.77-11.84
Depreciation & Amortization1.991.961.961.961.951.961.96
Stock Based Compensation99.965.952.533.281.500.000.00
Change in Working Capital6.022.93-0.76-1.150.771.170.08
Change in Accounts Payable5.671.37-1.48-0.241.490.000.00
Change in Other Working Capital0.353.04-0.42-0.911.480.000.00
Other Operating Activities-1.213.04-0.42-0.95-4.039.780.73
Net Cash from Operating Activities-69.10-24.94-20.78-27.77-25.22-17.38-11.68
Investing Activities
Capital Expenditures-0.220.00-0.01-0.020.010.02-0.01
Purchases of Investments-356.460.000.000.000.000.000.00
Sales/Maturities of Investments131.000.000.000.000.000.550.00
Other Investing Activities0.000.000.000.000.000.550.00
Net Cash from Investing Activities-225.680.00-0.01-0.02-0.010.53-0.18
Financing Activities
Debt Repayment49.890.000.00-0.01-0.020.000.00
Common Stock Issued148.96137.8614.110.0053.740.0016.30
Common Stock Repurchased0.000.00-0.02-0.120.000.000.00
Other Financing Activities14.1841.82-0.02-0.1253.7214.48-0.20
Net Cash from Financing Activities213.03180.0214.09-0.1353.7214.4817.83
Summary
Net Change in Cash-81.75155.08-6.70-27.9228.49-2.375.96
Cash at Beginning of Period169.6814.6021.3049.2220.7323.1017.14
Cash at End of Period87.93169.6814.6021.3049.2220.7323.10
Free Cash Flow-69.31-24.94-20.79-27.79-25.23-17.40-11.69